Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

About Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. For more information visit strataoncology.com.

About Us

In the news

The latest from Strata Oncology

April 25, 2025

Antibody Drug Conjugates Treatment Response Score (ADC TRS) for predicting ADC treatment response

Read more
April 25, 2025

Strata Oncology Announces Positive Results from Independent Evaluation of First of Its Kind Predictive Antibody Drug Conjugate (ADC) Biomarker

Read more
December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

Read more
November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

Read more
September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

Read more
September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

Read more
September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

Read more
July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

Read more
July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

Read more
June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

Read more